Other News To Note
Thursday, August 1, 2013
Elusys Therapeutics Inc., of Pine Brook, N.J., released data from three completed studies of ETI-204 (Anthim), an anthrax anti-toxin, administered by intramuscular injection (IM). Two of the studies assessed IM administration of ETI-204 following challenge with aerosolized B. anthracis spores (either before or after the development of symptoms of anthrax).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.